RNA Analysis Market Size, Share & Analysis Report, 2023-2032
The global RNA analysis market size was exhibited at USD 13.59 billion in 2022 and is projected to hit around USD 63.16 billion by 2032, growing at a CAGR of 16.61% during the forecast period 2023 to 2032.
Key Pointers:
RNA Analysis Market Report Scope
|
Report Coverage |
Details |
|
Market Size in 2023 |
USD 15.84 Billion |
|
Market Size by 2032 |
USD 63.16 Billion |
|
Growth Rate from 2023 to 2032 |
CAGR of 16.61% |
|
Base year |
2022 |
|
Forecast period |
2023 to 2032 |
|
Segments covered |
Technology, Product, Application, End-use |
|
Regional scope |
North America; Europe; Asia Pacific; Central and South America; the Middle East and Africa |
|
Key companies profiled |
Agilent Technologies; Bio-Rad Laboratories, Inc.; F. Hoffmann-La Roche AG; Illumina, Inc.; QIAGEN; Thermo Fisher Scientific, Inc.; Eurofins Scientific; Merck KGaA; Pacific Bioscience of California, Inc.; Affymetrix, Inc.; Danaher Corp.; Promega |
Transcriptomics is one of the most advanced fields in the post-genomic period. Technological advancements in this industry can be attributed to the increasing applications of transcriptome sequencing in life science for capturing polyadenylated RNA. With the expansion of next-generation high-throughput sequencing technology, the analysis of transcriptomes has been gradually improving the understanding of the regulatory network of RNA-based genes. For instance, in July 2021, the Lithuanian team is developing a droplet-based technique for simultaneous mRNA and microRNA capture and sequencing in a single cell.
The research is backed by the European Union with a USD174,000 Horizon 2020 research grant. Moreover, in May 2022, CD Genomics launched the Digital RNA sequencing technology, which is an NGS-based method that excludes sequence-dependent PCR. Such initiatives are anticipated to accelerate market growth shortly. Ribonucleic acid transcriptome analysis enables the researchers to analyze the position of genes as well as the functional patterns of a specific gene in an organism. The method assists in evaluating every transcript’s changing behavior at the development stage and assesses all the elements of a transcript, including messenger ribonucleic acid, non-coding ribonucleic acid, and micro ribonucleic acid, for identifying the transcriptional structure of genes.
The growing need for analyzing a huge number of genes to understand the gene-to-drug interactions is anticipated to enhance the application of transcriptomics technologies in discovery applications and drug development. For instance, transcriptome profiles of COVID-19 patients have been analyzed to examine the disease prognosis and management. Furthermore, increasing demand for personalized medicines is anticipated to fuel the industry growth during the forecast period. In April 2020, Caris Life Sciences announced the submission of Pre-Market Approval applications for MI Transcriptome CDx to the USFDA. It is a powerful precision medicine assay, which contains significant companion diagnostic biomarkers. On the other hand, data management in transcriptomic research and the lack of effective bioinformatics tools are some of the major challenges in the industry.
The evolution of high-throughput technologies has provided invaluable opportunities for generating holistic views of complex biological processes. Despite the considerable availability of omics data, the conversation of biological data into clinically valuable knowledge remains one of the major challenges. It is not only because of insufficient current data processing or integration methods but also for inappropriate application of existing analysis approaches. North America has been reported as the highest revenue-generating region in 2021 owing to increasing investments in pharmaceutical and biotechnology research by corporations. Asia Pacific is projected to register the fastest CAGR from 2022 to 2030 owing to the low-cost manufacturing services.
Technology Insights
On the basis of technologies, the global industry has been further divided into real time-PCR (qPCR), microarray, sequencing, and others. The real-time-PCR (qPCR) technology segment dominated the industry in 2022 and accounted for the maximum share of more than 44.09% of the global revenue. The high share was attributed to the wide usage of PCR for COVID-19 diagnostic across the globe. The qPCR technology is highly sensitive & quantitative and one of the most suitable methods for interrogating a comparatively small number of transcripts in a broad set of samples. PCR offers relatively high-sensitivity detection of SARS-CoV-2, evaluation of viral RNA in various types of clinical samples, detecting SARS-CoV-2 mutations, and evaluation of anti-SARS-CoV-2 drugs.
Thus, the COVID-19 pandemic served as a driving factor for industry growth. Also, quantitative Real-Time PCR is employed to conduct a comparative analysis of transcriptomes from the host and viral samples. Furthermore, sequencing is anticipated to witness substantial growth in the coming years owing to advancements in the next-generation and SMRT sequencing technology. The presence of several companies providing single-cell RNA sequencing services and the advent of bioinformatics algorithms are also driving the industry.
Product Insights
Based on products, the industry has been further sub-segmented into instruments, kits & reagents, and services. The kits & reagents products segment dominated the global market in 2022 and accounted for the maximum share of more than 60.19% of the overall revenue. Rising requirements for high-quality reagents and kits coupled with the repeated usage of reagents and media in transcriptome studies drive the growth of this segment. High-quality reagents and kits aid in delivering unmatched efficiency and strong performance ensure reliable and reproducible sequencing outcomes at a minimal cost.
Growing R&D activities in the pharmaceutical sector and increasing government investments in life science research are major factors expected to drivethe segment. NGS roots have begun with the adaptation of some SMART cDNA synthesis technology mainly for RNA-sequencing applications. In May 2022, Thermo Fisher Scientific, Inc. announced TaqPath SARS-CoV-2 CE-IVD RT-PCR Kit availability for international travel testing in the U.K. The kit is now entitled to clinics or laboratories in the surveillance. In addition, the PCR tests have been fundamental testing against SARS-CoV-2 in the United Kingdom since the inception of the pandemic.
Application Insights
The infectious diseases and pathogenesis application segment dominated the industry in 2022 and accounted for the largest share of more than 18.92% of the global revenue. The segment is estimated to expand further at the fastest CAGR during the forecast period. The identification of susceptible cells is crucial for understanding the pathogenic mechanism. Hence, there is increasing adoption of scRNA-sequencing to provide information about cell types susceptible to infection. Next-generation sequencing is transforming the health approach to infectious diseases and pathogenesis, as well as treating individuals.
Various methodologies have come for measuring gene expression and biomarkers for making their translation into clinical practice more feasible. The RNA structure and molecular dynamics segment is expected to register a significant CAGR from 2023 to 2032 as pharmaceutical importance for RNA in the development of a new drug are gradually increasing. In addition, molecular dynamics will also become a versatile tool to complement experimental investigations of RNA structural dynamics to provide opportunities for expanding the field and maximize gains from the molecular dynamic simulations, without any further methodological advances.
End-use Insights
The government institutes & academic centers segment reported the highest revenue share of more than 33.09% in 2022. The rising adoption rate of high throughput technologies for the effective process of RNA analysis by government institutes and academic centers drives the segment growth. Increasing applications of transcriptomics technologies in drug discovery are propelling the demand in the pharmaceutical as well as biotechnological industries. Similarly, research in drug discovery is also contributing to the market that is followed by clinical diagnostics. For instance, in April 2022, researchers developed TORNADO-seq, an RNA sequencing-based drug discovery platform to monitor the expression of the large gene for a detailed study of cellular phenotypes in organoids.
The Contract Research Organizations (CROs) segment is expected to grow at the fastest CAGR during the forecast period. Strategic activities by key market players support the segment growth. For instance, in Jan 2022, 10x Genomics announced the expansion of its 10x Certified Service Provider Network to incorporate three leading CROs. The CROs will partner with 10x Genomics to support leading biopharmaceutical companies seeking the advantage of 10x Genomics’ single-cell and spatial technologies to accelerate drug development and power novel therapeutic findings. The three CROs chosen for the 10x Genomics program are Azenta Life Sciences, Q2 Solutions, and CellCarta.
Regional Insights
North America accounted for the largest share of more than 43.85% in 2022. The growth is attributed to the rapid development of structure-based drug designs, increasing focus on transcriptomics research, and high investments in biopharmaceutical research and development. In addition, increasing investment in pharmaceutical research and drug development is the key factor that is accelerating the revenue growth of the companies in this region. However, Asia Pacific is projected to register the fastest CAGR during the forecast period. Growing investments by governments & enterprises are accelerating biotechnology research in the countries of Asia Pacific.
The Japanese government and non-government organizations are highly supportive of the growth of biotechnology research in the country and provide funds for research in the fields of medicine and life sciences. This encourages researchers to actively explore the transcriptomics space. Furthermore, increasing focus on APAC countries, owing to the low-cost manufacturing service, is expected to provide growth opportunities for the manufacturers. In addition, strategic activities, such as partnerships, will further augment the growth of this region. For instance, in January 2020, Genetron Holdings Ltd. entered into a strategic partnership agreement with Thermo Fisher Scientific to expand its precision cancer monitoring and diagnosis in China’s public hospitals.
Some of the prominent players in the RNA Analysis Market include:
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor, Inc. has segmented the global RNA Analysis market.
By Technology
By Product
By Application
By End-use
By Region
Chapter 1 Methodology And Scope
1.1 Research Methodology
1.2 Research Assumptions
1.2.1 Estimates and Forecast Timeline
1.3 Research Methodology
1.4 Information Procurement
1.4.1 Purchased Database
1.4.2 Nova one advisor’s Internal Database
1.4.3 Secondary Sources
1.4.4 Primary Research
1.4.5 Details Of Primary Research
1.5 Information Or Data Analysis
1.5.1 Data Analysis Models
1.6 Market Formulation & Validation
1.7 Model Details
1.7.1 Commodity Flow Analysis
1.7.1.1 Approach 1: Commodity Flow Approach
1.7.1.2 Approach 2: Country-Wise Market Estimation Using Bottom-Up Approach
1.8 Global Market: CAGR Calculation
1.9 List of Secondary Sources
1.10 List of Primary Sources
1.11 Objectives
1.11.1 Objective 1
1.11.2 Objective 2
Chapter 2 Executive Summary
2.1 Market Summary
Chapter 3 Market Variables, Trends & Scope
3.1 Market Segmentation
3.2 RNA Analysis Market Lineage Outlook
3.2.1 Parent Market Outlook
3.3 Penetration And Growth Prospect Mapping
3.4 Market Dynamics
3.4.1 Market Driver Analysis
3.4.1.1 Transcriptomics In Cancer Personalized/Precision Medicine
3.4.1.2 Rising Diagnostic Utility Of Transcriptomics Technologies
3.4.1.3 Advent Of Novel Approaches For Understanding Gene Expression At Rna Level
3.4.2 Market Restraint Analysis
3.4.2.1 Higher Cost Of Research And Developments
3.4.2.2 High Cost Associated With Platforms
3.4.3 Market Opportunity Analysis
3.4.3.1 Single Cell Transcriptomics And Associated Big Data
3.4.3.2 Advances In Sequencing Technologies
3.4.4 Market Challenge Analysis
3.4.4.1 Data Management In Transcriptomics Research
3.4.4.2 Lack Of Effective Bioinformatics Tools
3.5 Business Environment Analysis
3.5.1 SWOT Analysis; By factor (Political & Legal, Economic and Technological)
3.5.2 Porter’s Five Forces Analysis
3.6 Competitive Analysis
3.6.1 Recent Developments & Impact Analysis, By Key Market Participants
3.6.1.1 Strategy Framework
3.6.1.2 Market Participant Categorization
3.6.1.3 Major Deals & Strategic Alliances Analysis
3.6.1.3.1 Mergers And Acquisitions
3.6.1.3.2 Partnerships
3.6.1.3.3 Agreements
3.6.1.3.4 Synergies, Collaborations, And Other Initiatives
3.6.2 Market Entry Strategies
Chapter 4 Products Business Analysis
4.1 RNA Analysis Market: Products Movement Analysis
4.2 Instruments
4.2.1 Instruments market estimates and forecast, 2020 - 2032
4.3 Kits and Reagents
4.3.1 Kits and Reagents market estimates and forecast, 2020 - 2032
4.3.1.1 miRNA & siRNA
4.3.1.1.1 miRNA & SiRNA market estimates and forecast, 2020 - 2032
4.3.1.2 Reverse Transcriptases & RT-PCR
4.3.1.2.1 Reverse Transcriptase & RT-PCR market estimates and forecast, 2020 - 2032
4.3.1.3 RNA Extraction & Purification
4.3.1.3.1 RNA extraction & purification market estimates and forecast, 2020 - 2032
4.3.1.4 RNA Interference
4.3.1.4.1 RNA interference market estimates and forecast, 2020 - 2032
4.3.1.5 Others
4.3.1.5.1 Other market estimates and forecast, 2020 - 2032
4.4 Services
4.4.1. Services market estimates and forecast, 2020 - 2032
Chapter 5 Technology Business Analysis
5.1 RNA Analysis Market: Technology Movement Analysis
5.2 Real Time-PCR (qPCR)
5.2.1 Real Time-PCR (qPCR) market estimates and forecast, 2020 - 2032
5.3 Microarray
5.3.1 Microarray market estimates and forecast, 2020 - 2032
5.4 Sequencing
5.4.1 Sequencing market estimates and forecast, 2020 - 2032
5.5 Others
5.5.1 Other market estimates and forecast, 2020 - 2032
Chapter 6 Application Business Analysis
6.1 RNA Analysis Market: Application Movement Analysis
6.2 Construction of RNA Expression Atlas
6.2.1 Construction of RNA expression atlas market estimates and forecast, 2020 - 2032
6.3 Epigenetics
6.3.1 Epigenetics market estimates and forecast, 2020 - 2032
6.4 Infectious Diseases & Pathogenesis
6.4.1 Infectious diseases and pathogenesis market estimates and forecast, 2020 - 2032
6.5 Alternative RNA Splicing
6.5.1 Alternative RNA splicing market estimates and forecast, 2020 - 2032
6.6 RNA Structure & Molecular Dynamics
6.6.1 RNA structure and molecular dynamics market estimates and forecast, 2020 - 2032
6.7 Development & Delivery of RNA Therapeutics
6.7.1 Development and delivery of RNA therapeutics market estimates and forecast, 2020 - 2032
6.8 Others
6.8.1 Other market estimates and forecast, 2020 - 2032
Chapter 7 End-Use Business Analysis
7.1 RNA Analysis Market: End Use Movement Analysis
7.2 Government Institutes & Academic Centers
7.2.1 Government Institutes & Academic Centers estimates and forecast, 2020 - 2032
7.3 Pharmaceutical & Biotechnology Companies
7.3.1 Pharmaceutical & Biotechnology Companies estimates and forecast, 2020 - 2032
7.4 Hospitals & Clinics
7.4.1 Hospitals & Clinics estimates and forecast, 2020 - 2032
7.5 Contract Research Organizations (CROs)
7.5.1 Contract Research Organizations (CROs) estimates and forecast, 2020 - 2032
Chapter 8 Regional Business Analysis
8.1 RNA Analysis Market: Regional Movement Analysis
8.2 North America
8.2.1 North America Market Estimates And Forecast, 2020 - 2032
8.2.2 U.S.
8.2.2.1 U.S. market estimates and forecast, 2020 - 2032
8.2.2.2 U.S. RNA Analysis Market, by Product, 2020 - 2032
8.2.2.3 U.S. RNA Analysis Market, by Technology, 2020 - 2032
8.2.2.4 U.S. RNA Analysis Market, by Application, 2020 - 2032
8.2.2.5 U.S. RNA Analysis Market, by End-use, 2020 - 2032
8.2.3 Canada
8.2.3.1 Canada market estimates and forecast, 2020 - 2032
8.2.3.2 Canada RNA Analysis Market, by Product, 2020 - 2032
8.2.3.3 Canada RNA Analysis Market, by Technology, 2020 - 2032
8.2.3.4 Canada RNA Analysis Market, by Application, 2020 - 2032
8.2.3.5 Canada RNA Analysis Market, by End-use, 2020 - 2032
8.3 Europe
8.3.1 Europe Market Estimates And Forecast, 2020 - 2032
8.3.2 Germany
8.3.2.1 Germany market estimates and forecast, 2020 - 2032
8.3.2.2 Germany RNA Analysis Market, by Product, 2020 - 2032
8.3.2.3 Germany RNA Analysis Market, by Technology, 2020 - 2032
8.3.2.4 Germany RNA Analysis Market, by Application, 2020 - 2032
8.3.2.5 Germany RNA Analysis Market, by End-use, 2020 - 2032
8.3.3 U.K.
8.3.3.1 U.K. market estimates and forecast, 2020 - 2032
8.3.3.2 U.K. RNA Analysis Market, by Product, 2020 - 2032
8.3.3.3 U.K. RNA Analysis Market, by Technology, 2020 - 2032
8.3.3.4 U.K. RNA Analysis Market, by Application, 2020 - 2032
8.3.3.5 U.K. RNA Analysis Market, by End-use, 2020 - 2032
8.3.4 Italy
8.3.4.1 Italy market estimates and forecast, 2020 - 2032
8.3.4.2 Italy RNA Analysis Market, by Product, 2020 - 2032
8.3.4.3 Italy RNA Analysis Market, by Technology, 2020 - 2032
8.3.4.4 Italy RNA Analysis Market, by Application, 2020 - 2032
8.3.4.5 Italy RNA Analysis Market, by End-use, 2020 - 2032
8.3.5 Spain
8.3.5.1 Spain market estimates and forecast, 2020 - 2032
8.3.5.2 Spain RNA Analysis Market, by Product, 2020 - 2032
8.3.5.3 Spain RNA Analysis Market, by Technology, 2020 - 2032
8.3.5.4 Spain RNA Analysis Market, by Application, 2020 - 2032
8.3.5.5 Spain RNA Analysis Market, by End-use, 2020 - 2032
8.3.6 France
8.3.6.1 France market estimates and forecast, 2020 - 2032
8.3.6.2 France RNA Analysis Market, by Product, 2020 - 2032
8.3.6.3 France RNA Analysis Market, by Technology, 2020 - 2032
8.3.6.4 France RNA Analysis Market, by Application, 2020 - 2032
8.3.6.5 France RNA Analysis Market, by End-use, 2020 - 2032
8.4 Asia-Pacific
8.4.1 Asia-Pacific Market Estimates And Forecast, 2020 - 2032
8.4.2 Japan
8.4.2.1 Japan market estimates and forecast, 2020 - 2032
8.4.2.2 Japan RNA Analysis Market, by Product, 2020 - 2032
8.4.2.3 Japan RNA Analysis Market, by Technology, 2020 - 2032
8.4.2.4 Japan RNA Analysis Market, by Application, 2020 - 2032
8.4.2.5 Japan RNA Analysis Market, by End-use, 2020 - 2032
8.4.3 China
8.4.3.1 China market estimates and forecast, 2020 - 2032
8.4.3.2 China RNA Analysis Market, by Product, 2020 - 2032
8.4.3.3 China RNA Analysis Market, by Technology, 2020 - 2032
8.4.3.4 China RNA Analysis Market, by Application, 2020 - 2032
8.4.3.5 China RNA Analysis Market, by End-use, 2020 - 2032
8.4.4 India
8.4.4.1 India market estimates and forecast, 2020 - 2032
8.4.4.2 India RNA Analysis Market, by Product, 2020 - 2032
8.4.4.3 India RNA Analysis Market, by Technology, 2020 - 2032
8.4.4.4 India RNA Analysis Market, by Application, 2020 - 2032
8.4.4.5 India RNA Analysis Market, by End-use, 2020 - 2032
8.4.5 Australia
8.4.5.1 Australia market estimates and forecast, 2020 - 2032
8.4.5.2 Australia RNA Analysis Market, by Product, 2020 - 2032
8.4.5.3 Australia RNA Analysis Market, by Technology, 2020 - 2032
8.4.5.4 Australia RNA Analysis Market, by Application, 2020 - 2032
8.4.5.5 Australia RNA Analysis Market, by End-use, 2020 - 2032
8.4.6 South Korea
8.4.6.1 South Korea market estimates and forecast, 2020 - 2032
8.4.6.2 South Korea RNA Analysis Market, by Product, 2020 - 2032
8.4.6.3 South Korea RNA Analysis Market, by Technology, 2020 - 2032
8.4.6.4 South Korea RNA Analysis Market, by Application, 2020 - 2032
8.4.6.5 South Korea RNA Analysis Market, by End-use, 2020 - 2032
8.5 Latin America
8.5.1 Latin America Market Estimates And Forecast, 2020 - 2032
8.5.2 Brazil
8.5.2.1 Brazil market estimates and forecast, 2020 - 2032
8.5.2.2 Brazil RNA Analysis Market, by Product, 2020 - 2032
8.5.2.3 Brazil RNA Analysis Market, by Technology, 2020 - 2032
8.5.2.4 Brazil RNA Analysis Market, by Application, 2020 - 2032
8.5.2.5 Brazil RNA Analysis Market, by End-use, 2020 - 2032
8.5.3 Mexico
8.5.3.1 Mexico market estimates and forecast, 2020 - 2032
8.5.3.2 Mexico RNA Analysis Market, by Product, 2020 - 2032
8.5.3.3 Mexico RNA Analysis Market, by Technology, 2020 - 2032
8.5.3.4 Mexico RNA Analysis Market, by Application, 2020 - 2032
8.5.3.5 Mexico RNA Analysis Market, by End-use, 2020 - 2032
8.6 Middle East and Africa
8.6.1 Middle-East And Africa Market Estimates And Forecast, 2020 - 2032
8.6.2 South Africa
8.6.2.1 South Africa market estimates and forecast, 2020 - 2032
8.6.2.2 South Africa RNA Analysis Market, by Product, 2020 - 2032
8.6.2.3 South Africa RNA Analysis Market, by Technology, 2020 - 2032
8.6.2.4 South Africa RNA Analysis Market, by Application, 2020 - 2032
8.6.2.5 South Africa RNA Analysis Market, by End-use, 2020 - 2032
8.6.3 Saudi Arabia
8.6.3.1 Saudi Arabia market estimates and forecast, 2020 - 2032
8.6.3.2 Saudi Arabia RNA Analysis Market, by Product, 2020 - 2032
8.6.3.3 Saudi Arabia RNA Analysis Market, by Technology, 2020 - 2032
8.6.3.4 Saudi Arabia RNA Analysis Market, by Application, 2020 - 2032
8.6.3.5 Saudi Arabia RNA Analysis Market, by End-use, 2020 - 2032
Chapter 9 Company Profile
9.1.1 Agilent Technologies Inc.
9.1.1.1 Company overview
9.1.1.2 Financial performance
9.1.1.3 Product benchmarking
9.1.1.4 Strategic initiatives
9.1.2 Bio-Rad Laboratories, Inc.
9.1.2.1 Company overview
9.1.2.2 Financial performance
9.1.2.3 Product benchmarking
9.1.2.4 Strategic initiatives
9.1.3 F.Hoffman-La Roche LTD.
9.1.3.1 Company overview
9.1.3.2 Financial performance
9.1.3.3 Product benchmarking
9.1.3.4 Strategic initiatives
9.1.4 IllUMINA,INC.
9.1.4.1 Company overview
9.1.4.2 Financial performance
9.1.4.3 Product benchmarking
9.1.4.4 Strategic initiatives
9.1.5 QIAGEN
9.1.5.1 Company overview
9.1.5.2 Financial performance
9.1.5.3 Product benchmarking
9.1.5.4 Strategic initiatives
9.1.6 Thermo Fisher Scientific, INC.
9.1.6.1 Company overview
9.1.6.2 Financial performance
9.1.6.3 Product benchmarking
9.1.6.4 Strategic initiatives
9.1.7 Eurofins Scientific
9.1.7.1 Company overview
9.1.7.2 Financial performance
9.1.7.3 Product benchmarking
9.1.7.4 Strategic initiatives
9.1.8 Merck kgaA
9.1.8.1 Company overview
9.1.8.2 Financial performance
9.1.8.3 Product benchmarking
9.1.8.4 Strategic initiatives
9.1.9 Pacific Bioscience of California, Inc.
9.1.9.1 Company overview
9.1.9.2 Financial performance
9.1.9.3 Product benchmarking
9.1.9.4 Strategic initiatives
9.1.10 Affymetrix inc.
9.1.10.1 Company overview
9.1.10.2 Financial performance
9.1.10.3 Product benchmarking
9.1.10.4 Strategic initiatives
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers